662 related articles for article (PubMed ID: 25417902)
1. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
[TBL] [Abstract][Full Text] [Related]
4. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
7. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
[TBL] [Abstract][Full Text] [Related]
8. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
11. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Westin SN; Sill MW; Coleman RL; Waggoner S; Moore KN; Mathews CA; Martin LP; Modesitt SC; Lee S; Ju Z; Mills GB; Schilder RJ; Fracasso PM; Birrer MJ; Aghajanian C
Gynecol Oncol; 2019 Dec; 155(3):420-428. PubMed ID: 31623857
[TBL] [Abstract][Full Text] [Related]
12. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
Ragon BK; Odenike O; Baer MR; Stock W; Borthakur G; Patel K; Han L; Chen H; Ma H; Joseph L; Zhao Y; Baggerly K; Konopleva M; Jain N
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):431-440.e13. PubMed ID: 31056348
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract][Full Text] [Related]
17. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
19. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract][Full Text] [Related]
20. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]